Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q4 FY22 results · Jan–Mar 2022
Procter & Gamble Health reported revenue from operations of ₹267.82 crore (up 22.2% from Q4 FY21) and net profit of ₹51.16 crore (up 224.4% from Q4 FY21) for Q4 FY22 (Jan–Mar 2022), on a standalone basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 267.82 | 219.15 | +22.2% | 277.90 | −3.6% |
| Other income | 2.35 | 3.24 | −27.5% | 4.70 | −50.0% |
| Total income | 270.17 | 222.39 | +21.5% | 282.60 | −4.4% |
| Profit before tax | 64.86 | 26.10 | +148.5% | 59.83 | +8.4% |
| Net profit for the period | 51.16 | 15.77 | +224.4% | 44.84 | +14.1% |
| EPS, basic (₹) | 30.80 | 9.50 | +224.2% | 27.00 | +14.1% |
| Net margin (%) | 19.1 | 7.2 | 16.1 |
Standalone
- Filed with BSE
- 06 May 2022, 17:12 IST
- Board meeting
- 05 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE